TY - JOUR
T1 - Decreased peak expiratory flow rate associated with mortality in idiopathic pulmonary fibrosis
T2 - A preliminary report
AU - Fujita, Kohei
AU - Ohkubo, Hirotsugu
AU - Nakano, Akiko
AU - Takeda, Norihisa
AU - Fukumitsu, Kensuke
AU - Fukuda, Satoshi
AU - Kanemitsu, Yoshihiro
AU - Uemura, Takehiro
AU - Tajiri, Tomoko
AU - Maeno, Ken
AU - Ito, Yutaka
AU - Oguri, Tetsuya
AU - Ozawa, Yoshiyuki
AU - Murase, Takayuki
AU - Niimi, Akio
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2022/7
Y1 - 2022/7
N2 - Objectives: The peak expiratory flow rate (PEFR) is known to decrease in patients with sarcopenia. However, little is known about the clinical impact of the PEFR in idiopathic pulmonary fibrosis (IPF). This study aimed to confirm whether a decrease in PEFR over 6 months was associated with survival in IPF patients. Methods: Consecutive IPF patients who had been assessed at a single center were retrospectively analyzed. The relative decline in PEFR over 6 months was assessed. Survival analyses were performed by univariate and multivariate Cox proportional hazard models. Results: A total of 61 eligible cases (average age 70 years) were examined, and 21 patients (34.4%) died. The univariate Cox regression analysis showed that the body mass index, baseline % predicted forced vital capacity (FVC), baseline % predicted PEFR, % predicted diffusion capacity for carbon monoxide (DLCO), relative decline in FVC, and relative decline in PEFR were prognostic factors. On multivariate analyses, relative decline in PEFR (hazard ratio [HR] 1.037, p <.05) and baseline % predicted FVC (HR 0.932, p <.001) were independent prognostic factors, whereas relative decline in FVC was not. Conclusion: A decrease in PEFR after 6 months may predict worse survival in patients with IPF.
AB - Objectives: The peak expiratory flow rate (PEFR) is known to decrease in patients with sarcopenia. However, little is known about the clinical impact of the PEFR in idiopathic pulmonary fibrosis (IPF). This study aimed to confirm whether a decrease in PEFR over 6 months was associated with survival in IPF patients. Methods: Consecutive IPF patients who had been assessed at a single center were retrospectively analyzed. The relative decline in PEFR over 6 months was assessed. Survival analyses were performed by univariate and multivariate Cox proportional hazard models. Results: A total of 61 eligible cases (average age 70 years) were examined, and 21 patients (34.4%) died. The univariate Cox regression analysis showed that the body mass index, baseline % predicted forced vital capacity (FVC), baseline % predicted PEFR, % predicted diffusion capacity for carbon monoxide (DLCO), relative decline in FVC, and relative decline in PEFR were prognostic factors. On multivariate analyses, relative decline in PEFR (hazard ratio [HR] 1.037, p <.05) and baseline % predicted FVC (HR 0.932, p <.001) were independent prognostic factors, whereas relative decline in FVC was not. Conclusion: A decrease in PEFR after 6 months may predict worse survival in patients with IPF.
UR - http://www.scopus.com/inward/record.url?scp=85133586036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133586036&partnerID=8YFLogxK
U2 - 10.1177/14799731221114153
DO - 10.1177/14799731221114153
M3 - Article
C2 - 35792724
AN - SCOPUS:85133586036
SN - 1479-9723
VL - 19
JO - Chronic Respiratory Disease
JF - Chronic Respiratory Disease
ER -